The global Fructo-Oligosaccharides (FOS) market growth was valued at US$ 3.21 billion in 2022 and is projected to reach US$ 5.99 billion by 2031, growing at a CAGR of around 8.1% from 2024 to 2031.
Fructo-oligosaccharides are short-chain fructose-based carbohydrates widely used as soluble dietary fibres and prebiotics. They promote gut health, support digestive balance, and serve as...
The Type 1 Alpha-1 Antitrypsin Deficiency Treatment market, a rare genetic disorder in which the body produces insufficient alpha-1 antitrypsin protein leading to lung and liver damage is growing steadily. The market growth is driven by increasing disease awareness, improved diagnostic screening, the launch of new therapies (including augmentation therapies, gene therapies, RNA-based...
The global contact dermatitis treatment market is experiencing growth as the prevalence of contact dermatitis (both irritant and allergic types) increases worldwide, and as consumers and clinicians seek improved therapeutic and preventive options. Treatments typically include barrier creams, cleansers, topical and systemic medications, phototherapy and other modalities, targeted at minimizing...
The global mobile gamma cameras market value is poised for growth, driven by the increasing demand for portable diagnostic imaging equipment in hospitals, imaging centres and ambulatory settings. Mobile gamma cameras provide functional imaging of organs (such as cardiac, renal, brain, thyroid and breast) with flexibility to be used bedside or in situations where traditional fixed gamma...
The global polyethersulfone (PES) market value reached US$ 368.4 million in 2022 and is expected to reach US$ 658.5 million by 2031, growing at a CAGR of approximately 7.6 % during the forecast period 2024-2031.PES is a high-performance thermoplastic polymer known for its excellent thermal stability, chemical resistance, mechanical strength and dimensional stability. These properties...
The global SMA treatment market size was valued at US$ 4.40 billion in 2024 and is projected to reach US$ 13.09 billion by 2030, growing at a CAGR of 18.0% during the period 2025-2030.SMA is a rare genetic neuromuscular disorder characterised by progressive loss of motor neurons leading to muscle weakness and atrophy. Treatment options include gene replacement therapies, SMN-protein-modulating...
Apply for Your Account
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek
